Results 241 to 250 of about 66,762 (307)

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 14, Page 3970-3991, July 2026.
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander   +5 more
wiley   +1 more source

Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT2A receptor agonists

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 14, Page 3935-3949, July 2026.
Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture movements and a perceived concern about harm through recreational use, and their consequent legal prohibition in the early 1970s.
Trevor Sharp, Aurelija Ippolito
wiley   +1 more source

Association of Metabolic Score for Insulin Resistance With Resistant Hypertension and Hypertension in Obstructive Sleep Apnea

open access: yesThe Clinical Respiratory Journal, Volume 20, Issue 7, July 2026.
This study identifies the metabolic score for insulin resistance (METS‐IR) as an independent predictor of hypertension and resistant hypertension in obstructive sleep apnea (OSA). Crucially, this dose–response relationship is robust in severe OSA but attenuated in non‐severe cases, highlighting METS‐IR as a practical biomarker for risk stratification ...
Jinwei Xin   +5 more
wiley   +1 more source

S3‐Leitlinie Diagnostik und Therapie der Alopecia areata – Teil 1: Diagnostik und Epidemiologie

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 7, Page 1000-1016, July 2026.
Zusammenfassung In dem vom Innovationsausschuss beim gemeinsamen Bundesausschuss (G‐BA) geförderten Projekt wurde von 2023 bis 2025 die S3‐Leitlinie zur Diagnostik und Therapie der Alopecia areata (AA) entwickelt. Die interdisziplinäre Expertengruppe bestand aus Vertretern der Deutschen Dermatologischen Gesellschaft, insbesondere aus der AG ...
Ulrike Blume‐Peytavi   +13 more
wiley   +1 more source

S3 guideline diagnostics and therapy of alopecia areata – Part 1: Diagnostics and epidemiology

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 7, Page e1000-e1015, July 2026.
Summary In the project funded by the Innovation Committee at the G‐BA, the S3 guideline for the diagnosis and treatment of AA was developed between 2023 and 2025. The interdisciplinary expert panel consisted of representatives from the German Dermatological Society, in particular from the Pediatric Dermatology Working Group, the Professional ...
Ulrike Blume‐Peytavi   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy